Free Trial
NASDAQ:ONC

BeOne Medicines 8/6/2025 Earnings Report

BeOne Medicines logo
$307.30 -0.21 (-0.07%)
As of 02:35 PM Eastern

BeOne Medicines EPS Results

Actual EPS
$0.84
Consensus EPS
$0.48
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.32 billion
Expected Revenue
$1.24 billion
Beat/Miss
Beat by +$76.45 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

BeOne Medicines (NASDAQ:ONC) Stock Rating Upgraded by Wall Street Zen
The stealth altcoin the financial world is underestimating
This DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile

More Earnings Resources from MarketBeat